Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Equity (2016 - 2025)

Historic Return on Equity for Cytosorbents (CTSO) over the last 14 years, with Q3 2025 value amounting to 1.6%.

  • Cytosorbents' Return on Equity fell 3200.0% to 1.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.6%, marking a year-over-year decrease of 3200.0%. This contributed to the annual value of 1.2% for FY2024, which is 2000.0% down from last year.
  • Per Cytosorbents' latest filing, its Return on Equity stood at 1.6% for Q3 2025, which was down 3200.0% from 1.23% recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Return on Equity ranged from a high of 0.11% in Q1 2021 and a low of 1.7% during Q4 2024
  • In the last 5 years, Cytosorbents' Return on Equity had a median value of 0.97% in 2023 and averaged 0.95%.
  • In the last 5 years, Cytosorbents' Return on Equity surged by 13300bps in 2021 and then plummeted by -7300bps in 2022.
  • Quarter analysis of 5 years shows Cytosorbents' Return on Equity stood at 0.37% in 2021, then plummeted by -139bps to 0.88% in 2022, then tumbled by -57bps to 1.38% in 2023, then decreased by -23bps to 1.7% in 2024, then increased by 6bps to 1.6% in 2025.
  • Its last three reported values are 1.6% in Q3 2025, 1.23% for Q2 2025, and 1.24% during Q1 2025.